BIOMILQ, a biotech startup producing human breast milk from cultured cells, reveals its technology is on pace to reach the market in the next three to five years. Aiming to disrupt the $52 billion infant formula industry, BIOMILQ is working to combine the nutrition of breast milk with the convenience and practicality of formula.
Based in North Carolina, BIOMILQ raised $21M in Series A funding in 2021 from backers that included Bill Gates’ Breakthrough Energy Ventures.